You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for (1S,3R)-ACPD
(1S,3R)-ACPD is an active isomer of (±)-trans-ACPD. Agonist at both group I and II mGlu receptors (EC50 values are 5, 15, 42 and 60 μM at mGluR2, mGluR5, mGluR1 and mGluR6 respectively).
Technical Data for (1S,3R)-ACPD
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for (1S,3R)-ACPD
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for (1S,3R)-ACPD
The following data is based on the product molecular weight 173.17. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.3 mM||19.25 mL||96.24 mL||192.49 mL|
|1.5 mM||3.85 mL||19.25 mL||38.5 mL|
|3 mM||1.92 mL||9.62 mL||19.25 mL|
|15 mM||0.38 mL||1.92 mL||3.85 mL|
References for (1S,3R)-ACPD
References are publications that support the biological activity of the product.
Conti et al (2002) Synthesis and pharmacology of 3-hydroxy-Δ2-isoxazoline-cyclopentance analogues of glutamic acid. Farmaco 57 889 PMID: 12484537
Knopfel et al (1995) Metabotropic glutamate receptors: novel targets for drug development. J.Med.Chem. 38 1417 PMID: 7738999
Mistry and Challis (1996) Differences in agonist and antagonist activities for two indicies of metabotropic glutamate receptor-stimulated phosphoinositide turnover. Br.J.Pharmacol. 117 1735 PMID: 8732284
If you know of a relevant reference for (1S,3R)-ACPD, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: (1S,3R)-ACPD, (1S,3R)-ACPD supplier, Group, II, group, I, mGlur, agonists, Receptors, mGlu2, mGlu3, mGluR2, mGluR3, Glutamate, Metabotropic, mGlu1, mGlu5, mGluR1, mGluR5, (Metabotropic), 0284, Tocris Bioscience
6 Citations for (1S,3R)-ACPD
Citations are publications that use Tocris products. Selected citations for (1S,3R)-ACPD include:
Pasquale and Sherman (2013) A modulatory effect of the feedback from higher visual areas to V1 in the mouse. J Neurophysiol 109 2618 PMID: 23446698
Scholler (2017) HTS-compatible FRET-based conformational sensors clarify membrane receptor activation. Nat Chem Biol 13 372 PMID: 28135236
Andlauer et al (2014) Drep-2 is a novel synaptic protein important for learning and memory. J Neurosci 3 PMID: 25392983
Yamada et al (2008) Long-range axonal calcium sweep induces axon retraction. Sci Adv 28 4613 PMID: 18448637
Tang et al (2015) Stimulation-evoked Ca2+ signals in astrocytic processes at hippocampal CA3-CA1 synapses of adult mice are modulated by glutamate and ATP. J Neurosci 35 3016 PMID: 25698739
Blanco et al (2008) Tone-dependent vascular responses to astrocyte-derived signals. Am J Physiol Heart Circ Physiol 294 H2855 PMID: 18456724
Do you know of a great paper that uses (1S,3R)-ACPD from Tocris? Please let us know.
Reviews for (1S,3R)-ACPD
There are currently no reviews for this product. Be the first to review (1S,3R)-ACPD and earn rewards!
Have you used (1S,3R)-ACPD?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.